Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265969 | 1.00 | CTSS (0.49) | CTSSCTSKCACNA1BPPARAPPARG | |
| SCHEMBL17395943 | 1.00 | CTSS (0.49) | CTSSCTSKCACNA1BPPARAPPARG | |
| SCHEMBL8617411 | 0.87 | CTSS (0.45) | CTSSCTSKCACNA1BATMTACR1 | |
| SCHEMBL8615645 | 0.87 | CTSS (0.46) | CTSSCTSKCACNA1BPPARAPPARG | |
| SCHEMBL15226488 | 0.87 | CTSS (0.45) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL2707685 | 0.86 | KMT2A (0.47) | ATMKMT2A | |
| SCHEMBL205096 | 0.86 | KMT2A (0.47) | ATMKMT2A | |
| SCHEMBL205095 | 0.86 | KMT2A (0.47) | ATMKMT2A | |
| SCHEMBL30558136 | 0.85 | CTSS (0.41) | CTSSCTSKPPARAPPARGITGA4 | |
| SCHEMBL3815433 | 0.85 | CTSS (0.41) | CTSSCTSKPPARAPPARGITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-03-24 | — | — | US | disclosed |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-11-11 | — | — | US | disclosed |
| WO-2020047251-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582644-B2 | O-GlcNAc transferase inhibitors and uses thereof | OGA, OGT, OSTC | CTSS 1495/4885CTSK 3504/4885CACNA1B 3079/4885 |
| US-20210346367-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGT, OGA, UGGT1 | CTSS 897/4885CTSK 1546/4885CACNA1B 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.